Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis - Takeaways - MDSpire

Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis

  • By

  • Nobuyoshi Kittaka

  • Hideaki Tahara

  • Takashi Akazawa

  • Yu Mizote

  • Takashi Kitajima

  • Keiichi Minami

  • Yurika Sugano

  • Takahiro Nakayama

  • June 16, 2026

  • 0 min

Share

  • 1

    Chemotherapy-induced peripheral neuropathy (CIPN) is a major adverse effect of paclitaxel in breast cancer patients.

  • 2

    Neurofilament light chain (NfL) levels significantly increase in patients with CIPN, serving as a potential biomarker for early detection.

  • 3

    Galectin-3 levels showed no significant changes between patients with and without CIPN during the study.

  • 4

    Proteomic analysis identified alcohol dehydrogenase 4 (ADH4) upregulation and vesicular overexpressed in cancer prosurvival protein 1 (VOPP1) downregulation in CIPN.

  • 5

    The study highlights the need for integrating biomarkers and proteomics to enhance precision medicine in managing chemotherapy-induced toxicities.

Original Source(s)

Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis

  • by Nobuyoshi Kittaka, Hideaki Tahara, Takashi Akazawa, Yu Mizote, Takashi Kitajima, Keiichi Minami, Yurika Sugano, Takahiro Nakayama

  • June 16, 2026

Related Content

RSPO2-induced ferroptosis via PTBP1-mediated FSP1 mRNA decay suppresses breast cancer progression

The role of LARP1 in breast cancer progression: from prognosis to immune microenvironment remodeling

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib